|
|
 Previous Article | Table of Contents | Next Article 
Induction and enhancement by monocytes of antibody-induced modulation of a
variety of human lymphoid cell surface antigens
RW Schroff, MM Farrell, RA Klein, HC Stevenson and NL Warner
We have previously reported that the addition of monocytes results in
enhanced modulation of the T65 antigen when normal or leukemic lymphoid
cells were cultured in vitro with the T101 monoclonal antibody. In the
present investigation, we extend these findings to demonstrate that
monocyte-enhanced modulation is a phenomenon that occurs with a variety of
T and B lymphoid antigens identified by murine monoclonal antibodies. Two
patterns of monocyte-enhanced modulation were observed: (1) augmentation by
monocytes of existing antigen modulation by the T101 and anti-Leu-4
antibodies, and (2) induction by monocytes of previously unrecognized
modulation with the anti-Leu-2 and anti-Leu-9 antibodies. Enhancement of
modulation by monocytes was also detected with antibodies to surface IgM
and HLA-DR antigens. Antigen modulation on lymphoid cell lines appeared to
be more variable than on fresh cells, with or without monocytes.
Monocyte-enhanced antigen modulation was not demonstrated with two
monoclonal antibodies against solid tumors. Monocyte-enhanced modulation
was shown to be dependent upon the Fc portion of the antibody, but
independent of proteolytic or oxidative compounds released by monocytes.
These findings indicate that the results obtained during in vitro studies
of antigen modulation may vary with the source of cells and the extent to
which monocytic cells are present. In addition, these findings suggest an
enhanced role for Fc receptor-bearing cells of monocytic origin in antigen
modulation following in vivo administration of monoclonal antibodies.
Volume 66,
Issue 3,
pp. 620-626,
09/01/1985
Copyright © 1985 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y. Li, M. E. Williams, J. B. Cousar, A. W. Pawluczkowycz, M. A. Lindorfer, and R. P. Taylor
Rituximab-CD20 Complexes Are Shaved from Z138 Mantle Cell Lymphoma Cells in Intravenous and Subcutaneous SCID Mouse Models
J. Immunol.,
September 15, 2007;
179(6):
4263 - 4271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Williams, J. J. Densmore, A. W. Pawluczkowycz, P. V. Beum, A. D. Kennedy, M. A. Lindorfer, S. H. Hamil, J. C. Eggleton, and R. P. Taylor
Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia
J. Immunol.,
November 15, 2006;
177(10):
7435 - 7443.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. V. Beum, A. D. Kennedy, M. E. Williams, M. A. Lindorfer, and R. P. Taylor
The Shaving Reaction: Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Cells by THP-1 Monocytes
J. Immunol.,
February 15, 2006;
176(4):
2600 - 2609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
